Scheme illustrating the interaction network of inner ring complex (IRC) constituents within the NPC scaffold (EMDB code 3103; (von Appen et al., 2015) ), adapted from (Lin et al., 2016) . Nup98 and Nup53 are predicted to adopt an extended configuration and to engage into multiple interactions with partner nucleoporins. CDK1 and PLK1 phosphorylation sites in Nup98 and Nup53 are depicted by black and white bars, respectively. The identified PLK1 phosphorylation site in Nup53 is indicated in red. (A) Nup98 contains an epitope phosphorylated by PLK1. Phosphorylation of Nup98 at NPCs during prophase renders a Nup98 epitope inaccessible to a mouse monoclonal antibody (Laurell et al., 2011) . Treatment of mitotic cells with the PLK1 inhibitor BI2536 restored recognition of Nup98 by the monoclonal antibody. In brief, nocodazole-arrested mitotic cells were treated with either DMSO (D) or the PLK1 inhibitor BI2536 (BI) for 1 hr. Cells were harvested and lysed. Aliquots of the cell extract derived from DMSO-treated control cells were either mock-treated or incubated with alkaline phosphatase (CIP). Samples were analyzed by immunoblotting using the indicated antibodies. Note that a rabbit (rb) polyclonal antibody directed against Nup98 recognizes both the phosphorylated and dephosphorylated forms of Nup98, whereas the mouse monoclonal (m) antibody only binds to Nup98 upon inhibition of PLK1 or after dephosphorylation.
(B) The phosphorylation-sensitive epitope of Nup98 resides between residues 684 and 705 of Nup98. The indicated fusions between GFP and protein fragments derived from the C-terminal domain of Nup98 were expressed in HeLa cells. Interphase cell extracts were analyzed by immunoblotting using either the rabbit polyclonal (rb) or mouse (m) monoclonal antibodies against Nup98.
(C) A protein fragment comprising residues 678-714 of human Nup98 is efficiently phosphorylated by PLK1 in vitro. Recombinant, purified His 6 -tagged zz or His 6 -tagged zzNup98(678-714) (Coomassie) were incubated with [γ-
32 P]-ATP in the absence or presence of recombinant, purified PLK1. Incorporation of 32 P was analyzed by autoradiography.
(D) In vitro phosphorylation (autoradiograph) of recombinant zz-Nup98(678-714) (Coomassie) by an activity present in mitotic cell extract is impaired upon PLK1 inhibition or immunodepletion of PLK1.
(E) Mutation of T691, S692 or S697 to Glu impairs or reduces recognition of GFP-Nup98(506-863) by the mouse monoclonal Nup98 antibody. The indicated protein fusions were expressed HeLa cells and analyzed by immunoblotting using either the rabbit polyclonal (rb) or mouse (m) monoclonal antibodies against Nup98.
(F) In vitro phosphorylation of recombinant, purified His-tagged Nup98(506-863) variants (Coomassie) by PLK1. Incorporation of 32 P was analyzed by autoradiography.
(G) GFP-Nup98 wt or mutant variants in which the 5 PLK1 consensus sites were rendered to phosphodeficient Ala or phosphomimetic Glu residues were expressed in HeLa cells. Cell extracts were analyzed by immunoblotting using either the rabbit polyclonal (rb) or mouse (m) monoclonal antibodies against Nup98. Pull-down experiment from mitotic HeLa cell extracts using GST-PBD WT or GST-PBD AA as baits (as in Figure 5A ). 4% of the input and 20% of the eluates were analyzed by immunoblotting with the indicated antibodies. (B) HeLa cell lines expressing either GFP-Nup53 WT or GFP-Nup53 16A(CDK1) were depleted of endogenous Nup53 by RNAi and synchronized by a thymidine block. 10 hr after release, cell were fixed, stained with Hoechst (DNA) and analyzed by immunofluorescence using an anti-PLK1 antibody as in Figure 3A . Scale bar, 10 µm.
(C) Quantification of the experiment shown in B. Late prophase cells identified based on the localization of condensed chromatin at the nuclear periphery were assigned to one of three categories: PLK1 enriched at the NE; PLK1 reduced at the NE; PLK1 barely visible at the NE. WT , GFP-Nup53 S314A or GFP-Nup53 S314C . Scale bar, 10 µm.
(B) Quantification of GFP intensity across the NE of experiment in A by averaging line scans. n ≥ 50 cells per condition.
(C) Immunoblot analysis of GFP-Nup53 variants expressed in HeLa cells as in Figure 6A and Figure S6A .
(D) Cell lines stably expressing GFP-Nup53 from an RNAi-resistant transgene were treated with an siRNA targeting the coding sequence of Nup53 and used for in vitro NEBD (Figure 6 ). Downregulation of endogenous Nup53 was verified by immunoblotting. The asterisk indicates the endogenous protein.
(E) Representative images derived from in vitro NPC disassembly experiments shown in Figure  6C ,D.
. Scale bar, 10 µm.
(F) Representative images of immunofluorescence analysis of NPCs (mAb414 antibody) in cells used for in vitro NPC disassembly experiments shown in Figure 6 . Imaging was performed using STED. Scale bars, 5 µm upper panels, 1 µm lower panels.
(G) Quantification of NPC numbers of the experiment shown in F. 
